Phaseline

Targets › SELE

SELE (E-selectin): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout May 2027.

Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. (UniProt, P16581)

Open in Phaseline: the race on SELE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Uproleselan
Selectin E antagonist
SELEPhase 2Acute Myeloid Leukemia; Acute Myeloid Leukemia Post Cytotoxic TherapyMay 2027

Conditions

Acute Myeloid Leukemia (1) Acute Myeloid Leukemia Post Cytotoxic Therapy (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.